Scholarlink

Objective <p>To evaluate the efficacy and safety of belimumab combined with standard therapy in children with systemic lupus erythematosus (SLE) in a single-center retrospective observational cohort.</p> Methods <p>A total of 60 children with active SLE were screened, and 40 eligible patients were included. Patients were classified into a belimumab plus standard therapy group (<i>n</i> = 20) and a standard therapy alone group (<i>n</i> = 20). Belimumab was administered intravenously at 10&#xa0;mg/kg every 2 weeks for the first three doses and every 4 weeks thereafter. Clinical manifestations, laboratory parameters, SLEDAI-2000 scores, glucocorticoid doses, and adverse events were compared between groups. The 6-month assessment was considered the primary observation time point, while 12-month outcomes were exploratory.</p> Results <p>At 6 months, renal and mucocutaneous remission rates were 83% (15/18) and 94% (15/16) in the belimumab group, compared with 78% (7/9) and 85% (11/13) in the control group. At 12 months, the corresponding rates were 94% (15/16) and 94% (15/16) in the belimumab group, and 89% (8/9) and 85% (11/13) in the control group. C3, C4, and SLEDAI-2000 scores improved significantly in both groups. Most clinical and serological outcomes did not differ significantly between groups. Oral glucocorticoid doses decreased more markedly in the belimumab group than in the control group (53.55 ± 8.43 to 6.72 ± 3.50&#xa0;mg/day vs. 55.50 ± 6.05 to 14.81 ± 5.54&#xa0;mg/day; <i>P</i> &lt; 0.05). One patient experienced reversible reductions in IgG levels and B-cell counts, with no severe infections or infusion reactions.</p> Conclusions <p>Belimumab plus standard therapy showed a potential glucocorticoid-sparing effect in pediatric SLE, but larger prospective studies are needed to confirm its efficacy and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of belimumab in children with systemic lupus erythematosus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Ying Yang,
  • Tianji Gao,
  • Shaonan Xu,
  • Bei Xu

摘要

Objective

To evaluate the efficacy and safety of belimumab combined with standard therapy in children with systemic lupus erythematosus (SLE) in a single-center retrospective observational cohort.

Methods

A total of 60 children with active SLE were screened, and 40 eligible patients were included. Patients were classified into a belimumab plus standard therapy group (n = 20) and a standard therapy alone group (n = 20). Belimumab was administered intravenously at 10 mg/kg every 2 weeks for the first three doses and every 4 weeks thereafter. Clinical manifestations, laboratory parameters, SLEDAI-2000 scores, glucocorticoid doses, and adverse events were compared between groups. The 6-month assessment was considered the primary observation time point, while 12-month outcomes were exploratory.

Results

At 6 months, renal and mucocutaneous remission rates were 83% (15/18) and 94% (15/16) in the belimumab group, compared with 78% (7/9) and 85% (11/13) in the control group. At 12 months, the corresponding rates were 94% (15/16) and 94% (15/16) in the belimumab group, and 89% (8/9) and 85% (11/13) in the control group. C3, C4, and SLEDAI-2000 scores improved significantly in both groups. Most clinical and serological outcomes did not differ significantly between groups. Oral glucocorticoid doses decreased more markedly in the belimumab group than in the control group (53.55 ± 8.43 to 6.72 ± 3.50 mg/day vs. 55.50 ± 6.05 to 14.81 ± 5.54 mg/day; P < 0.05). One patient experienced reversible reductions in IgG levels and B-cell counts, with no severe infections or infusion reactions.

Conclusions

Belimumab plus standard therapy showed a potential glucocorticoid-sparing effect in pediatric SLE, but larger prospective studies are needed to confirm its efficacy and safety.